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Background. Beside the lipid-lowering effect, statins slow the progression of atherosclerosis by exerting anti-inflammatory and
platelet inhibiting effects. We investigated whether platelet inhibition by simvastatin correlates with the statin effects on lipid
lowering, inflammation, oxidative stress, and endothelial and platelet activation. Methods. In hypercholesterolemic patients
allocated to diet (n=20) or a 2-month treatmentwith diet plus 40mg simvastatin (n=25), we evaluated platelet aggregating responses
to ADP, collagen, and arachidonic acid (AA), the effect of aspirin on AA-induced aggregation, pro- and anti-inflammatory and
atherogenic mediators (IL-1𝛽, -5, -6, -7, -8, -9, -10, -12, and -13, IFN-𝛾, IP-10, Eotaxin, and sRAGE), markers of endothelium (sE-
selectin, VEGF, andMCP-1) and platelet activation (sP-selectin, sCD-40L, RANTES, and PDGF-bb), and oxidative stress (8-OH-2’-
deoxyguanosine).Results. After treatment, beside the improvement of lipid profile, we observed the following: a reduction of platelet
aggregation to ADP (p=0.0001), collagen (p=0.0001), AA (p=0.003); an increased antiaggregating effect of aspirin in the presence
of AA (p=0.0001); a reduction of circulating levels of IL-6 (p=0.0034), IL-13 (p<0.0001), IFN-𝛾 (p<0.0001), VEGF (p<0.0001), sE-
selectin (p<0.0001), sCD-40L (p<0.0001), sP-selectin (p=0.003), and 8-OH-2’-deoxyguanosine (p<0.0001); an increase of IL-10
and sRAGEs (p=0.0001 for both). LDL-cholesterol levels (i) positively correlated with IL-6, IFN-𝛾, E-selectin, sCD-40L, 8-OH-2’-
deoxyguanosine, platelet aggregation to ADP, collagen, AA, and aspirin IC-50 and (ii) negatively correlated with IL-10 and sRAGE.
In multiple regression analyses, LDL-cholesterol was the strongest predictor for most parameters of platelet reactivity. Conclusion.
In primary hypercholesterolemia, simvastatin treatment reduced platelet activation and subclinical inflammation and improved
endothelial dysfunction. LDL-cholesterol levels were the major correlate of platelet reactivity; however, other effects of statins may
contribute to reducing the progression of atherosclerosis.
1. Introduction
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase (statins) are the most relevant
drugs used to lower serum cholesterol levels. In chronic
therapy, they are highly effective in the prevention of
cardiovascular events [1]. Furthermore, they slow the
progression of atherosclerosis by mechanisms related not
only to the cholesterol lowering effect, but also to the
so-called “pleiotropic” effects, including the influence on
subclinical chronic inflammation and haemostasis [2–6].
In particular, statins exert anti-inflammatory properties
[7] and inhibit that of the proinflammatory cytokines [8].The
anti-inflammatory effect of statins has been attributed to their
ability to reduce, by inhibitingHMG-CoA reductase, not only
cholesterol synthesis but also the activation of themevalonate
pathway, with the consequent reduction of isoprenylated
and geranylgeranylated proteins, and in particular of Ras
prenylation. The statin-induced Ras inhibition reduces the
activity of the transcription factor nuclear factor kappa B
(NF-kB), which is involved in a wide range of inflammatory
pathways and in the formation of reactive oxygen species
(ROS) [9]. This statement is confirmed by the observation
that high dose simvastatin reduces the binding activity of the
proinflammatory transcription factorNF-kB and the concen-
trations of inflammatory molecules, while the combination
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of low dose simvastatin with ezetimibe, resulting in a similar
low-density lipoprotein (LDL)-cholesterol reduction, does
not affect the inflammatory markers [10].
Effects of statins on endothelial function, immunomod-
ulation, and thrombogenesis could play a role in their
ability to prevent cardiovascular events, to ameliorate the
prognosis of patients affected by acute myocardial infarc-
tion, and to reduce the risk of restenosis after coronary
angioplasty [11]. In particular, simvastatin has been shown
to exert endothelial beneficial effects by promoting nitric
oxide production [12], vasorelaxation [13, 14], and improving
leukocyte/endothelium interactions [15]. However, it is still
debated whether these effects contribute to an additional
cardiovascular risk reduction beyond that expected from
LDL-cholesterol lowering [11, 16–18].
Links between chronic inflammation and atherothrom-
bosis are very tight [19] and involve platelets, which interact
with endothelial cells and leukocytes by adhesion molecules
and trigger inflammation by releasing proinflammatory
molecules [20–22].
The mechanisms of inflammation-induced thrombo-
sis, including the relationships between inflammation and
platelet function, have been reviewed [23].
Platelets derived from patients with elevated plasma
LDL-cholesterol show in vitro hyperaggregability, increased
fibrinogen binding and surface expression of P-selectin, and
increased production of thromboxane A
2
(TXA
2
) and of
superoxide anion, whereas plasma derived from the same
patients contains increased concentrations of platelet activa-
tion markers, such as soluble CD40 ligand (sCD-40L) and
beta-thromboglobulin [24].
The statin-induced reduction of platelet activity has been
associated with changes of LDL-cholesterol, oxidized-LDL,
and P-selectin [25].
The relationships between statin effects on inflammatory
molecules and platelet function have been addressed by very
few studies. A peculiar aspect of the antiplatelet effect of
statins is their ability to reduce the so-called “aspirin resis-
tance”, a phenomenon associatedwith adverse cardiovascular
outcomes and increasedmortality,more frequent in hyperlip-
idaemic patients than in general population [26]. From the
biochemical point of view, elevated cholesterol reduces the
aspirin-mediated platelet acetylation, a mechanism involved
in the aspirin-induced antiaggregating effect, exerted via the
irreversible inhibition of TXA
2
biosynthesis [27]. Therapy
with statins is able to significantly reduce platelet TXA
2
formation in patients taking low dose of aspirin [28].
Furthermore, in vitro experiments carried out by platelet
incubation with pravastatin or simvastatin and aspirin
demonstrate that statins improve the aspirin-induced platelet
inhibition, suggesting that they directly interact with platelet
membranes (though these interactions do not include statin’s
effects on membrane cholesterol or membrane permeability)
and modulate signalling pathways in platelets [29].
On the other hand, some “in vivo” studies demonstrating
a platelet inhibiting effect of statins after only few days of
treatment suggest an effect largely independent of cholesterol
lowering [25, 30, 31]. Thus, some mechanisms involved in
platelet inhibition occur before any reduction of cholesterol
concentrations.
In summary, literature data show that statins exert a
platelet antiaggregating effect, but it is still not clear whether
it is mediated by statin effects on LDL-cholesterol, or inflam-
mation, or both, or by direct statin effects on platelets.
We designed this study to investigate the association
between the platelet inhibitory effect of simvastatin with
the lipid lowering and a wide spectrum of pro- and anti-
inflammatory, pro- and anti-atherogenic markers induced
by the drug in patients affected by primary hypercholes-
terolemia.
2. Methods
2.1. Subjects, Materials, and Methods. We investigated forty-
five patients affected by newly diagnosed primary hyper-
cholesterolemia. They did not have a family history of
diabetes mellitus and were otherwise healthy on the basis
of medical history, physical examination, and standard
diagnostic procedures; in particular, they did not present
arterial hypertension, impaired fasting glucose, or impaired
glucose tolerance measured by the oral glucose tolerance
test (OGTT), congestive heart failure, previous peripheral or
coronary or cerebral ischemic vascular diseases, endocrine
diseases (including hypothyroidism), renal, hepatic, or hepa-
tobiliary diseases, and myopathic or haemostatic disorders.
From the study, we also excluded patients on treatment
with nonsteroidal anti-inflammatory or antiplatelet drugs, or
antioxidant supplements in the previous threeweeks. Patients
were randomized to be treated with diet plus simvastatin
40 mg/die for two months (n=25) or diet alone without
pharmacological intervention (n=20). All patients followed
a low-fat diet close to the Adult Treatment Panel (ATP)
III guidelines (7% energy from saturated fat and 200 mg
dietary cholesterol per day). The study was approved by the
Ethics Committee of San Luigi Gonzaga Hospital and all
participants authorized data use for investigational purpose
by signed informed consent. At baseline and after two
months, all subjects were submitted to a clinical evaluation
and in fasting venous blood samples we assessed the following
parameters.
(A) Metabolic Parameters and Insulin. Glucose, total and
HDL-cholesterol, triglycerides, and apolipoprotein B (Apo
B)-100weremeasured by automated chemistry by theCentral
Laboratory of our hospital. LDL-cholesterol was calculated
according to the Friedwald’s formula. Insulin was measured
by a radioimmunoassay kit (Biochem Immuno System,
Bologna, Italy). Insulin sensitivity in the fasting state was
estimated using HOMA-IR index by the following formula:
fasting plasma glucose (mmol/l) x fasting serum insulin
(𝜇U/ml) divided by 22.5. HOMA-IR is commonly used in
clinical studies as a reliable marker of insulin resistance [32].
(B) Markers of Inflammation, Endothelial and Platelet
Activation, and Oxidative Stress. They are as follows: (i)
proinflammatory, proatherogenic cytokines and chemokines:
Interleukin-1𝛽 (IL-1𝛽), Interleukin-5 (IL-5), Interleukin-6
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(IL-6), Interleukin-7 (IL-7), Interleukin-8 (IL-8), Interleukin-
9 (IL-9), Interleukin-12 (IL-12), Interleukin-13 (IL-13),
Interferon-Inducible Protein (IP-10), Interferon-𝛾 (IFN-𝛾),
Eotaxin, and Monocyte Chemoattractant Protein-1 (MCP-
1); (ii) anti-inflammatory and antiatherogenic markers:
Interleukin-10 (IL-10) and Soluble Receptor of Advanced
GlycationEndProducts (sRAGE); (iii)markers of endothelial
activation: Vascular Endothelial Growth Factor (VEGF) and
soluble E-selectin (sE-selectin); (iv) markers of in vivo
platelet activation: soluble P-selectin (sP-selectin), sCD-
40L, Platelet Derived Growth Factor-BB (PDGF-BB),
and RANTES; (v) a marker of in vivo oxidative stress:
8-hydroxy-2’-deoxyguanosine (8-OHdG).
Serum and plasma samples for biomarkers detectionwere
stored at -80∘C until assayed.
Serum concentrations of IL-1𝛽, IL-5, IL-6, IL-7, IL-8, IL-
9, IL-10, IL-12, IL-13 IFN-𝛾, IP-10, Eotaxin, MCP-1, VEGF,
RANTES, and PDGF-bb were measured in duplicate by
using the Bio-Plex cytokine assay (Bio-Rad Laboratories Inc.,
Hercules, CA, USA) according to manufacturer’s instruc-
tions. The Bio-Plex system combines the principle of a
sandwich immunoassay with the Luminex fluorescent-bead-
based technology allowing the simultaneous measurement of
many cytokines.
Serum levels of sE-selectin, sP-selectin, sRAGE, and
sCD40L were measured in duplicate with enzyme-linked
immunosorbent assay kits (R&D Systems, Abingdon, United
Kingdom) according to manufacturer’s instructions.
Serum levels of 8-OH-dG were measured by a com-
petitive enzyme-linked immunosorbent assay (Bioxytech 8-
OHdG-EIA, OXIS Health Products, Portland, Oregon).
(C) Platelet Function Assays. (i) Platelet aggregation: venous
blood samples were withdrawn without stasis and anti-
coagulated with 3.8% sodium citrate, pH 7.4 (1ml for 9
ml of blood). Platelet-rich plasma (PRP) was obtained by
using the Platelet FunctionCentrifuge (BioDataCorporation,
Horsham, PA), designed to provide a rapid separation of PRP
by a centrifugation for 30 sec. From the top, only two-thirds
of the supernatant were collected to avoid contamination by
other circulating cells and the remaining blood was further
centrifugated for 180 sec to obtain platelet-poor plasma
(PPP).
PRP samples were stimulated by arachidonic acid (AA)
(1mmol/l), ADP (10 𝜇mol/l), and collagen (4 mg/l) (Mascia
Brunelli, Milan, Italy) and platelet aggregation was measured
as light-scattering changes by using an eight-channel aggre-
gation system (Platelet Aggregation Profiler, PAP-8, BioData
Corporation) according to the Born’s method [33]. Platelet
aggregation in response to agonists was reported as maximal
aggregation (MA). Each aggregation test was recorded for 5
min after the addition of the agonist.
(ii) Platelet sensitivity to aspirin: PRP obtained as
described above was stimulated by AA (1 mmol/l) in the
absence (see above) and in the presence of a 30 min prein-
cubation with lysine acetylsalicylate (L-ASA) (1-50 𝜇mol/l)
(Sanofi-Aventis, Milan, Italy). Platelet aggregation was mea-
sured as described above.
2.2. Statistical Analysis. Data are expressed as mean ± SD.
Normality of data was checked using Shapiro–Wilk test.
Continuous data was examined using parametric analyses
performed by Student’s t-test for paired and unpaired data.
Data are given as mean ± standard deviation (SD). Data
with a non-Gaussian distribution were analysed using the
Mann–Whitney U test and Wilcoxon signed-rank test, as
appropriate. Univariate linear regression analysis was per-
formed to assess the correlation of lipid parameters with
circulating biomarkers and platelet aggregation. Pearson’s
correlation was used to examine the significance of corre-
lation between variables. To evaluate the combined effects
of different variables on the platelet parameters, we used
a multivariate linear regression model with a backward
approach. All analyses were performed with SPSS v.24.
3. Results
The clinical characteristics of the investigated subjects at
baseline and after two months with or without simvastatin
therapy are shown in Table 1. At baseline, anthropometric
and clinical and metabolic parameters did not significantly
differ between the two groups. After twomonths, in the group
of patients treated with simvastatin we found, as expected, a
significant reduction of total and LDL-cholesterol and of Apo
B-100, whereas no differences were found in control group.
3.1. Changes in Inflammatory, Atherogenic, and Oxidative
Stress Markers. Table 2 shows circulating levels of inflam-
matory, atherogenic, and oxidative stress markers before and
after the two months of follow-up. At baseline no differences
were found between the two groups for each investigated
biomarker. After two months, in simvastatin-assigned group,
significant reductions of IL-6 (27%, p<0.01), IL-8 (14%,
p<0.05), IL-13 (38%, p<0.0001), IFN-𝛾 (52%, p<0.0001), and
8-OH-dG (28%, p<0.0001) and significant increases of IL-10
(104%, p<0.0001) and sRAGE (55%, p<0.0001)were found. In
control group, all these parameters did not change.
3.2. Changes in Endothelial andPlatelet ActivationMarkers. A
two-month treatment with simvastatin induced a significant
decrease of the endothelial dysfunction markers sE-selectin
(33%, p<0.0001) and VEGF (30%, p<0.0001) (Figure 1). As far
as platelet activation markers are concerned, we observed a
significant reduction of sP-selectin (21%, p=0.003) and sCD-
40L (41%, p<0.0001) whereas RANTES and PDGF-BB did
not change (Figure 2). In patients who served as controls, no
difference for each investigated parameter was found.
3.3. Changes in Platelet Aggregability. As shown in Figure 3,
when platelet aggregation tests were evaluated, a two-month
treatment with simvastatin resulted in a decrease of MA
values in response to ADP (22%, p<0.0001), collagen (21%,
p<0.0001), and AA (19%, p<0.0001). In the same subjects, an
improvement of the platelet sensitivity to the antiaggregating
effects of aspirin was also observed as mirrored by the
decrease of L-ASA IC-50 in the presence of AA (65%,
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Table 1: Clinical characteristics of hypercholesterolemic patients at baseline and after two months of treatment with diet alone (control) or
simvastatin.
Control (n=20) Simvastatin (n=25)
Before After p-value Before After p-value
Male/Female M=9 / F=11 - - M=11 / F=14 - -
Age (years) 55±11 - - 59±13 - -
BMI (kg/m2) 25±3 25±3 0.4913 25±4 25±4 0.3698
TC (mg/dl) 270±43 269±50 0.8300 282±30 185±27 <0.0001
HDL-C (mg/dl) 47±5 48±4 0.1523 48±9 48±7 0.3851
LDL-C-C (mg/dl) 188±45 185±51 0.7584 196±33 107±25 <0.0001
APO B-100 (mg/dl) 157±17 155±16 0.3153 152±17 93±15 <0.0001
TG (mg/dl) 177±44 175±48 0.7146 190±61 149±43 0.0027
FG (mg/dl) 87±9 85±8 0.3372 88±9 88±8 0.8580
HOMA-IR 2.6±1.3 2.5±1 0.4331 2.6±1.2 2.4±1 0.9678
SBP (mmHg) 123±7 124±7 0.7199 126±12 125±10 0.2075
DBP(mmHg) 81±6 80±4 0.7239 79±7 79±7 0.9715
Data are presented as mean±SD. TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; APO B,
apolipoprotein B; TG, triglycerides; FG; fasting glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure. For p value, paired Student’s t-test or
Wilcoxon test was used as appropriate.
Table 2: Pro- and anti-inflammatory and oxidative stress markers in subjects at baseline and after two months of treatment with diet alone
(control) or simvastatin.
Control (n=20) Simvastatin (n=25)
Before After p value Before After p value
Pro-inflammatory
IL-1b 0.98±0.63 0.94±0.46 0.5008 0.86±0.45 0.79±0.41 0.3625
IL-5 1.8±0.7 1.6±0.7 0.1043 2.0±1.7 2.2±1.4 0.1742
IL-6 6.7±2.5 6.7±2.4 0.6404 6.6±3.4 4.8±2.2 0.0034
IL-7 5.9±2.1 5.7±1.0 0.6676 5.6±2.5 4.9±1.9 0.2143
IL-8 16.8±4.3 15.6±4.0 0.1919 18.9±6.0 16.3±6.7 0.0447
IL-9 18.5±6.6 17.8±7.6 0.4428 17.7±11.6 19.0±15.2 0.6186
IL-12 22.8±7.3 21.4±6.8 0.5124 22.0±13 22.8±13 0.7145
IL-13 5.9±2.2 6.0±2.8 0.6864 7.3±4.3 4.5±2.7 <0.0001
IFN-𝛾 32.7±14.4 34.0±16.2 0.6744 38.1±13.6 18.3±7.5 <0.0001
IP-10 519±226 476±195 0.1960 491±219 521±264 0.6189
Eotaxin 177±63 177±46 0.7509 143±67 167±54 0.0534
MCP-1 57±23 60±16 0.5257 60±45 50±31 0.1906
Anti-Inflammatory
IL-10 1.07±0.55 1.04±0.51 0.7046 1.03±0.56 2.10±0.51 <0.0001
sRAGE 678±268 659±248 0.4637 740±263 1147±310 <0.0001
Oxidative Stress
8-OH-dG 1.60±0.56 1.62±0.58 0.9038 1.84±0.59 1.33±0.56 <0.0001
Data are presented as mean ± SD. IL, interleukin; MCP, Monocyte Chemoattractant Protein; sRAGE, Soluble Receptor of Advanced Glycation End Products;
8-OH-dG, 8-hydroxy-2’-deoxyguanosine. Concentrations are expressed as pg/ml, except where otherwise indicated. For p value, paired Student’s t-test or
Wilcoxon test was used as appropriate.
p=0.0001). In patients who served as controls, no difference
for each investigated platelet function parameter was found.
3.4. Correlation Studies. As shown in Table 3, univariate
regression analysis between lipid profile and all circulating
markers and aggregability parameters of all patients at base-
line revealed that LDL-cholesterol levels are (i) positively
associated with IFN-𝛾, IL-6, VEGF, E-selectin, and sCD-40L
as circulating markers of inflammation, endothelial dysfunc-
tion, and in vivo platelet activation, respectively, 8-OH-dG
as marker of oxidative stress, platelet aggregation to ADP,
collagen, AA, and IC-50 L-ASA and (ii) inversely associated
with the anti-inflammatory markers IL-10 and sRAGE. No
significant correlations were found for triglycerides levels
(data not shown). Interestingly, when a similar analysis was
carried out on the data after simvastatin we found a positive
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Figure 1: Box-plot analysis of the endothelial dysfunction markers E-selectin and vascular endothelial growth factor (VEGF) in
hypercholesterolemic patients assigned to diet alone (Control) or to diet plus simvastatin (Simva) at baseline (pre) and after a two-month
follow-up (post). Significance of intragroup differences was estimated by paired t-test or Wilcoxon test, as appropriate. Solid lines: median
values; boxes: interquartile range; whiskers: nonoutlier range; closed circles: outliers.
Table 3: Correlation between LDL-C and pro- and anti-
inflammatory, oxidative stress, and platelet activation markers
in hypercholesterolemic patients at baseline.
LDL-C
r p
IFN-𝛾 0.493 0.001
IL-6 0.427 0.003
VEGF 0.301 0.044
E-Selectin 0.560 <0.0001
sCD-40L 0.348 0.019
IL-10 -0.364 0.014
sRAGE -0.484 0.001
8-OH-dG 0.307 0.040
MAADP 0.638 <0.0001
MACOLL 0.614 <0.0001
MAAA 0.623 <0.0001
IC-50 L-ASA 0.600 <0.0001
IFN, interferon; IL, interleukin; VEGF, vascular endothelial growth fac-
tor; sCD-40L, soluble CD-40 ligand; IL, interleukin; sRAGE, Soluble
Receptor of Advanced Glycation End Products; 8-OH-dG, 8-hydroxy-2’-
deoxyguanosine; MA, maximal aggregation; Coll, collagen; AA, arachidonic
acid; IC-50, half-maximal inhibitory concentration; L-ASA, lysine acetylsal-
icylate.
correlation between LDL-cholesterol and E-selectin (r=0.616,
p=0.001) and 8-OH-dG (r=0.500, p=0.011).
Correlation between platelet aggregability and the inves-
tigated pattern of circulating biomarkers in all patients at
baseline is shown inTable 4. Of note, independently of proag-
gregating stimulus, an increased platelet aggregation and
a reduced antiaggregating effect of aspirin were associated
with increase of E-selectin, IFN-𝛾, and IL-6, thus pointing
out the relationships between impaired endothelial function,
inflammation, and platelet hyperaggregability. Interestingly,
in this context also reduced levels of the anti-inflammatory
sRAGE played a role in increasing platelet response to
activators (ADP, AA) and decreasing the inhibitory effect of
L-ASA.
When the differences between values at baseline and after
two months of simvastatin treatment (delta values) of LDL-
cholesterol were correlated with the delta values of all the
evaluated parameters, no significant correlation was found
(data not shown).
Table 5 shows the multiple linear regression analysis
with MA to ADP, collagen, and AA and with L-ASA IC-50
to AA entered as dependent variables and the parameters
significantly correlated with them (see Table 4) entered as
independent variables.
The significant predictors were for MA to ADP, LDL-
cholesterol, VEGF, p-selectin, sRAGE; for MA to collagen,
LDL-cholesterol alone; for MA to AA, LDL-cholesterol, IL-
1b, IL-10, and sCD40L; and for L-ASA IC-50 to AA, LDL-
cholesterol and sCD40L.
4. Discussion
This study, carried out in patients with primary hypercholes-
terolemia, shows that a two-month therapy with simvastatin
improved not only, as expected, the lipid profile but also a
wide pattern of proatherogenic and prothrombotic param-
eters. Actually, simvastatin treatment reduced mediators of
inflammation, oxidative stress, and endothelial and platelet
activation, increased anti-inflammatory circulating markers,
reduced platelet aggregating responses to ADP, collagen, and
AA and increased platelet sensitivity to aspirin.
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Figure 2: Box-plot analysis of the platelet activation markers soluble P-selectin (sP-selectin), Rantes, soluble CD-40 ligand (sCD-40L), and
platelet-derived growth factor (PDGF)-BB, in hypercholesterolemic patients assigned to diet alone (Control) or to diet plus simvastatin
(Simva) at baseline (pre) and after a two-month follow-up (post). Significance of intragroup differences was estimated by paired t-test or
Wilcoxon test, as appropriate. Solid lines: median values; boxes: interquartile range; whiskers: nonoutlier range; closed circles: outliers.
To the best of our knowledge, this is the first study
which simultaneously considered a so wide spectrum of the
potential simvastatin effects, trying to correlate themwith the
platelet effects of the drug.
On the other hand, at baseline, a correlation was observed
between LDL-cholesterol levels andmarkers of inflammation
(such as IL-6 and IFN-g), of anti-inflammation (such as
IL-10 and sRAGE), endothelial activation markers (such
as sE-selectin, VEGF), platelet activation markers (such as
sCD-40L), oxidative stress (such as 8-OH-dG), and platelet
function parameters evaluated in terms of aggregation to
activators (i.e., collagen, AA, and ADP) or response to
inhibitor (i.e., L-ASA). The biological explanation of this
phenomenon is attributable to the role exerted by LDL-
cholesterol on subclinical inflammation, oxidative stress, and
platelet activation, as previously mentioned.
The role of LDL-cholesterol on platelets is suggested by
evidence showing that lipoprotein disorders affect platelet
function. Actually, LDL particles sensitize platelets by the
binding of apoB-100 to the specific receptor on the platelet
membrane and the subsequent modification of platelet func-
tion via a wide spectrum of interactions: in particular, LDL
particles in their native form induce hypersensitivity of
platelets to agonists resulting in increased aggregation and
secretion responses whereas, after oxidation, they become
independent platelet activators in stirred platelet suspensions
[34].
In our study, when platelet function parameters were
correlated with biomarkers at baseline, we observed the
occurrence of significant correlations not only with LDL-
cholesterol, but also with proinflammatory (such as IL-1b,
IL-6, and IFN-𝛾), anti-inflammatory (such as IL-10 and
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Figure 3: Box-plot analysis showing maximal aggregation to ADP, collagen, arachidonic acid (AA), and lysine acetylsalicylate (L-ASA) half-
maximal inhibitory concentration (IC-50) in the presence of AA in hypercholesterolemic patients assigned to diet alone (Control) or to diet
plus simvastatin (Simva) at baseline (pre) and after a two-month follow-up (post). Significance of intragroup differences was estimated by
paired t-test or Wilcoxon test, as appropriate. Solid lines: median values; boxes: interquartile range; whiskers: nonoutlier range.
sRAGE), endothelial activation (such as sE-selectin, VEGF),
and platelet activation (sP-selectin, sCD-40L, and PDGF-BB)
markers. In themultivariate analysis, LDL-cholesterol was the
parameter that more strongly influenced platelet sensitivity
to activators (ADP, collagen, and AA) and inhibitor (aspirin)
suggesting a primary role for LDL-cholesterol in determining
the cascade of inflammatory events responsible also for the
activated platelet function.
In our study, lack of correlations between most of
biomarkers levels and LDL-cholesterol after simvastatin sug-
gests that some pleiotropic effects of simvastatin may be inde-
pendent of their effects on LDL-cholesterol levels. However,
a positive and significant correlation after simvastatin was
found with E-selectin and 8-OH-dG and this fact induces
hypothesizing that the improvement of cholesterol levels may
alone influence some peculiar aspects of endothelial function
and oxidative stress.
On the other hand, we did not observe significant cor-
relations between delta values of LDL- cholesterol and delta
values of all the parameters modified by the simvastatin treat-
ment (data not shown). Although this fact is not surprising
and fits with other observations in literature, we are aware,
however, that the limited number of subjects enrolled in our
study could be a possible explanation for the absence of sig-
nificant correlations between delta values of LDL- cholesterol
and delta values of all the parameters modified after statin
treatment. However, from the biological point of view, the
plausibility of this phenomenon could be also due to the fact
that themechanisms bywhich statins exert the lipid-lowering
and the pleiotropic effects are different, although the first step
is the inhibition of HMG-CoA reductase. Furthermore, the
demonstration of a direct effect of the statins on platelets
observed in “in vitro” experiments [29, 35] further increases
the complexity of the picture.
Of course, the interplay between inflammation and
thrombosis is enhanced in the presence of dyslipidemia: not
surprisingly, statins, which reduce both lipid concentrations
and inflammation, are considered antithrombotic drugs, as
reviewed [36, 37].
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Table 4: Correlation between platelet function, expressed as maxi-
mal aggregation (MA) to ADP (a), collagen (b), AA, and L-ASA IC-
50 (d), and pro- and anti-inflammatory, oxidative stress, and platelet
activation markers in hypercholesterolemic patients at baseline.
(a) MA to ADP
r p
IFN-𝛾 0.391 0.008
IL-6 0.384 0.009
VEGF 0.326 0.029
P-Selectin 0.326 0.029
E-Selectin 0.432 0.003
sRAGE -0.453 0.002
(b) MA to collagen
r p
IFN-𝛾 0.326 0.029
IL-6 0.327 0.028
PDGF-BB 0.331 0.027
E-Selectin 0.419 0.004
(c) MA to AA
r p
IFN-𝛾 0.315 0.035
IL-10 -0.448 0.002
IL-1b 0.320 0.032
IL-6 0.425 0.004
E-Selectin 0.515 0.0003
sCD-40L 0.562 <0.0001
sRAGE -0.515 0.0003
(d) L-ASA IC-50 to AA
r p
IL-6 0.347 0.020
E-Selectin 0.339 0.023
sCD-40L 0.442 0.002
sRAGE -0.454 0.002
TC, total cholesterol; LDL-C, low-density lipoprotein; IFN, interferon; IL,
interleukin; VEGF, vascular endothelial growth factor; sCD-40L, soluble
CD-40 ligand; IL, interleukin; sRAGE, Soluble Receptor of Advanced Gly-
cation End Products; PDGF, Platelet Derived Growth Factor; Coll, collagen;
AA, arachidonic acid; IC-50, half-maximal inhibitory concentration; L-
ASA, lysine acetylsalicylate.
The so-called “pleiotropic effects” of statins on endothe-
lial function, vascular inflammation, immunomodulation,
and thrombogenesis could play a role in their ability to
prevent cardiovascular events, to ameliorate the prognosis
of patients affected by acute myocardial infarction, and to
reduce the risk of restenosis after angioplasty, as reviewed
[17], even if it is still debated whether these effects contribute
an additional cardiovascular risk reduction beyond that
expected from LDL-cholesterol lowering [11, 16–18].
A previous study demonstrated that simvastatin inhibits
TXA
2
biosynthesis and platelet function in hypercholes-
terolemic patients [38, 39]. Also other statins reduce platelet
function. In particular, fluvastatin therapy reduced platelet
cholesterol/phospholipid molar ratio and platelet aggre-
gation, suggesting that its antiaggregating effect is due
to reduced platelet cholesterol content [40]. Atorvastatin
therapy reduced collagen-induced platelet aggregation [41],
platelet activation evaluated by flow cytometry [42], and
platelet function in patients with coronary heart disease [43].
Pravastatin, as well as simvastatin, reduced platelet thrombus
formation after only 8 weeks of therapy [44]. The statin-
induced reduction of platelet activity has been associatedwith
changes of LDL-cholesterol, oxidized-LDL, and P-selectin
[25]. Our study extends previous studies by showing the
inhibiting effects of simvastatin treatment on pathways of
platelet aggregation activated by three different agonists
and on the L-ASA antiaggregating effect. Furthermore, we
observed that simvastatin reduced sCD40L and sP-selectin
levels as markers of platelet activation.
As previously mentioned, statins are able to reduce the
so-called “aspirin resistance”, a phenomenon associated with
adverse cardiovascular outcomes and increased mortality
[26]. Actually, in our study simvastatin therapy showed the
ability to significantly improve the in vitro platelet sensitivity
to the antiaggregating effects of aspirin, a finding consistent
with data obtained by other authors showing a reduced TXA
2
formation in patients treated with simvastatin and receiving
aspirin before and after statin administration [28].
In the present study we observed an effect of simvastatin
treatment on a variety of markers of inflammation and we
evaluated the relationships between the statin effects on
inflammatory molecules and platelet function, an aspect
addressed by few studies. It has been shown that eight
weeks of treatment with atorvastatin and rosuvastatin are
associated with comparable reductions in LDL-cholesterol,
high sensitive C reactive protein (hsCRP), 11-dehydro-TXB
2
(a marker of TXA
2
biosynthesis), and 8-iso-prostaglandin
F
2𝛼
(a marker of lipid peroxidation with platelet-activating
properties): in this study, inmultiple regression analyses, only
hsCRP and LDL-cholesterol were independent predictors of
11-dehydro-TXB
2
, while only LDL-cholesterol predicted 8-
iso-PGF
2𝛼
[45]. Notably, we showed for the first time that
simvastatin treatment is also able to significantly reduce
circulating sRAGE concentrations. It is known that sRAGE
levels are reduced in hypercholesterolemic patients as com-
pared to healthy subjects and inversely correlate with urinary
excretion of isoprostanes and plasma asymmetric dimethyl-
arginine suggesting that the ligand-RAGE axis may link
endothelial dysfunction with oxidative stress [46].
5. Conclusions
In conclusion, this study provides the first evidence that a
short-term treatment with simvastatin simultaneously affects
awide range ofmarkers of inflammation and atherothrombo-
sis, adding a piece of information to better clarify the rationale
of simvastatin therapy in patients at a high cardiovascular
risk. In fact, simvastatin therapy, beside its hypocholes-
terolemic effect, (i) decreases oxidative stress, proatherogenic
and proinflammatory markers, (ii) increases antiatherogenic
and anti-inflammatory markers, (iii) reduces platelet aggre-
gation to physiological agonists, and (iv) increases platelet
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Table 5: Multivariate regression analysis between baseline platelet function values, expressed as maximal aggregation (MA) to ADP (a),
collagen (b), AA, and L-ASA IC-50 (d), entered as dependent variable, and markers of lipid control, inflammation, endothelial dysfunction,
oxidative stress, and platelet activation markers, entered as independent variables. The table shows the final regression parameters after a
backward selection algorithm in which all variables were present in the first step.
(a) MA to ADP
MA to ADP Adjusted R2=0.362 F=25.954 p<0.0001
Constant B=7.072 p=0.7299
LDL-C B=0.250 p=0.0016
VEGF B=0.191 p=0.0081
p-Selectin B=0.134 p=0.0009
sRAGE B=-0.021 p=0.0510
(b) MA to collagen
MA to Collagen Adjusted R2=0.393 F=15.239 p<0.0001
Constant B=31.722 p=0.0069
LDL-C B=0.290 p<0.0001
(c) MA to AA
MA to AA Adjusted R2=0.615 F=18.580 p<0.0001
Constant B=21.873 p=0.0946
LDL-C B=0.211 p=0.0003
IL-10 B=-8.762 p=0.0240
IL-1b B=9.012 p=0.0128
sCD-40L B=1.549 p=0.0013
(d) L-ASA IC-50 to AA
L-ASA IC-50 to AA Adjusted R2=0.394 F=15.302 p<0.0001
Constant B=1.406 p=0.8282
LDL-C B=0.132 p=0.0002
sCD-40L B=0.609 p=0.0398
sensitivity to the antiaggregating effects of aspirin. In this
scenario, LDL-cholesterol levels are a major correlate and
possibly a determinant of enhanced platelet reactivity sug-
gesting a primary role for LDL-cholesterol in determining
the cascade of inflammatory events responsible also for the
impaired platelet function.
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